Skip to main content

Advertisement

Table 2 Efficacy assessments from baseline to end point (LOCF analysis)

From: Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

  Placebo, n = 83 Paliperidone palmitate
Efficacy measure   234/39 mg, n = 72 234/156 mg, n = 72 234/234 mg, n = 85
PANSS total score
   Baseline, mean (SD) 92.6 (9.2) 95.8 (8.9) 94.5 (7.9) 96.0 (9.2)
   LS mean (SE) change from baseline -9.8 (2.8) -15.4 (2.7) -18.7 (2.8) -20.7 (2.8)
   P value for LS mean (vs placebo) -- 0.046 0.001 <0.001
CGI-S score
   Baseline, mean (SD) 5.1 (0.3) 5.2 (0.4) 5.1 (0.2) 5.1 (0.3)
   LS mean (SE) change from baseline -0.9 (0.2) -1.1 (0.2) -1.3 (0.2) -1.5 (0.2)
   P value for LS mean (vs placebo) -- 0.387 0.023 0.003
PSP score
   Baseline, mean (SD) 42.9 (10.1) 41.3 (10.4) 44.7 (11.5) 41.0 (10.1)
   LS mean (SE) change from baseline 10.3 (2.2) 11.5 (2.1) 15.1 (2.2) 17.7 (2.2)
   P value for LS mean (vs placebo) -- 0.597 0.028 0.0005
  1. Each paliperidone palmitate subject received 234 mg of paliperidone palmitate on day 1 and then their assigned dose day 8 and monthly thereafter.
  2. CGI-S = Clinical Global Impression-Severity scale; LOCF = last-observation-carried-forward; LS = least-squares; PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance.